Authors
Mariusz Sowa, Joanna Sowa
Published in
Medical science monitor : international medical journal of experimental and clinical research. Volume 32. Pages e952805. Jun 20, 2026. Epub Jun 20, 2026.
Abstract
This narrative review synthesizes published evidence regarding antiplatelet therapy strategies used during coil embolization of ruptured intracranial aneurysms, with particular emphasis on coil-only treatment and distinctions between coil-only and device-assisted procedures. The available literature suggests that antiplatelet therapy can reduce periprocedural thromboembolic complications, particularly in selected coil-only cases; however, evidence for consistent benefit in delayed cerebral ischemia, functional outcomes, or long-term recovery remains limited and heterogeneous. Importantly, findings from stent-assisted or flow-diverter-treated cohorts should not be directly extrapolated to coil-only procedures - antiplatelet therapy in device-assisted treatment is largely driven by implant-related thrombogenicity. The current evidence base is limited by retrospective study designs, single-center cohorts, heterogeneous treatment protocols, and inconsistent endpoint definitions. At present, no standardized antiplatelet regimen can be recommended for routine use in coil-only aneurysmal subarachnoid hemorrhage. Ongoing randomized studies, including the ASTOP trial, may help clarify the benefit-risk balance and determine whether a more evidence-based, procedure-specific antiplatelet strategy can be established.
PMID:
42322037
Bibliographic data and abstract were imported from PubMed on 20 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 1
- Comments 0